Navigation Links
Interviewed Experts Expect Taxotere to Increase Overall Survival More Than Other Drugs, Including Lupron Depot, in Stage III Prostate Cancer
Date:4/6/2009

A Drug That Improves Survival Would Earn a 50 Percent Patient Share in the U.S. and a 40 Percent Patient Share in Europe, According to a New Report from Decision Resources

WALTHAM, Mass., April 6 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed oncologists identify a therapy's effect on overall survival as the attribute that most influences their prescribing decisions in stage III prostate cancer. Clinical data and the opinions of interviewed thought leaders indicate that Sanofi-Aventis's Taxotere has advantages in this attribute over LHRH agonists, including Abbott's Lupron Depot, the sales-leading agent in the market.

The new report entitled Stage III Prostate Cancer: Oncologists Ready for New Type of Therapy finds that a drug that improves five-year disease-specific survival would earn a 50 percent patient share in stage III prostate cancer in the United States and a 40 percent patient share in Europe, according to surveyed U.S. and European oncologists.

In 2007, Decision Resources' proprietary clinical gold standard for stage III prostate cancer was Lupron Depot. Based on available data and expert opinion, Ferring Pharmaceuticals' degarelix will earn gold-standard status for stage III prostate cancer in 2012. Interviewed experts anticipate that degarelix, which has competitive advantages and has shown impressive Phase III clinical trial data, will be more effective than Lupron Depot.

"Interviewed experts are optimistic about the efficacy of some emerging agents in this market, most notably degarelix and Taxotere," said Decision Resources Analyst Natalia Reoutova. "In terms of improvements to survival, Taxotere, which has been approved for use in metastatic hormone-refractory prostate cancer, remains the most promising therapy for stage III prostate cancer and some interviewed physicians are already using it off-label."

About the Report

Stage III Prostate Cancer: Oncologists Ready for New Type of Therapy is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                 Decision Resources, Inc.
    Christopher Comfort                Elizabeth Marshall
    781-296-2597                       781-296-2563
    ccomfort@dresources.com            emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. In Hepatitis C Virus Treatment, Interviewed Experts Indicate That Telaprevir- and Boceprevir-Based Regimens Have Advantages Over Pegasys/Ribavirin in Sustained Virologic Response
2. My1Stop.com President Michael Del Chiaro Interviewed by Entrepreneur.com for ecommerce Expertise
3. National Experts Offer Practical Tips for Parents Concerned about Autism
4. Covance Experts to Present Key Insights on Risk Management at Bio/Pharmaceutical Drug Safety Forum
5. Surveyed Experts Indicate that Biogen Idecs Adentri Has Advantages Over Nitroglycerin in the Treatment of Acute Heart Failure
6. Experts turn to Web to combat distressing skin disease
7. Surveyed Experts Indicate That Xarelto Has Advantages Over Lovenox in the Treatment of Venous Thromboembolism in Medically Ill Patients
8. Experts from Africa and Asia to Discuss Maternal Health in Live Online Chat
9. FDA Experts to Speak at RAPS Horizons Conference
10. Experts Revise Guidelines on Daily Aspirin for Heart
11. Experts Weigh in on Controversial Issue of Determining Value of Cancer Care at NCCN Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2017)... ... August 18, 2017 , ... Paragon and ... database to help the cannabis industry move towards greater legitimacy. By incorporating IOTA’s ... faster technology with lower fees. Paragon will build a fully verifiable database to ...
(Date:8/19/2017)... ... August 19, 2017 , ... Yesterday, the President of the United States ... two sides. There are not two sides to hatred, bigotry, discrimination, and a white ... and the NPEIV stands against all forms of such hatred and discrimination in this ...
(Date:8/18/2017)... ... August 18, 2017 , ... More than 20,000 pairs of shoes made ... thanks to an ambitious venture that conjoined the passions of an NBA star, a ... the Liberty community. These shoes will save lives from the rampant infections transmitted through ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... ... “Vision & Hearing” campaign, advocating for active, healthy lifestyles and highlighting the importance ... for individuals with hearing impairments and shares the latest innovations in hearing aid ...
(Date:8/18/2017)... ... August 18, 2017 , ... Moore Insurance, a Houston area ... Texas, is launching a regional charity effort to provide publicity assistance and generate ... Brain Tumor Foundation (PBTF) has raised nearly $30 million in donations that has ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... Board of Directors has approved the payment of a quarterly ... The cash dividend of ... 27, 2017 to stockholders of record as of the close ... are subject to approval of the Board of Directors and ...
(Date:8/7/2017)...  Endo International plc (NASDAQ: ENDP ) ... all known U.S. mesh product liability claims and that ... remaining U.S. claims at reasonable values. Under the agreements, ... quarter of 2017 and continuing through the fourth quarter ... results, the Company intends to increase its mesh product ...
(Date:8/3/2017)... SAN DIEGO , Aug. 3, 2017  Opioid ... crippling diseases driving up healthcare costs and threatening outcomes, ... the lab supply and IVD industry that support them, ... health care market researcher said that drugs of abuse, ... vendors and sessions at the organization,s 69th meeting in ...
Breaking Medicine Technology: